This article is more than 5 years old. Information may no longer be current.
VIDEO: PEGASUS-TIMI 54 analysis shows reduced risk for MACE in patients with diabetes
Click Here to Manage Email Alerts
CHICAGO — At the American College of Cardiology Scientific Session, Deepak L. Bhatt, MD, MPH, provides investigator insight on a new PEGASUS-TIMI 54 analysis that suggests pooled doses of ticagrelor plus aspirin reduced the risk for MACE compared with placebo in patients with and without diabetes.
The PEGASUS TIMI-54 trial investigated the efficacy and safety of ticagrelor 60 mg and 90 mg twice daily on top of aspirin in patients with recent MI prior to study enrollment and one additional risk factor for atherothrombotic CV events. Results of the overall trial demonstrated that treatment with ticagrelor (Brilinta, AstraZeneca) reduced the risk for CV death, MI or stroke in this population.
The new analysis presented at the American College of Cardiology Scientific Session examined those patients with diabetes at baseline and found a risk reduction in CV death and minor stroke of about 16%, which is similar to the overall trial, according to Bhatt, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart and Vascular Center, professor of medicine at Harvard Medical School and Cardiology Today’s Intervention Chief Medical Editor.
A particularly interesting finding, he said, was a significant reduction in CV death and CHD-related death among diabetic patients that was not observed among non-diabetic patients.
These results, “in a sense, echo back to an older era and what was seen with intravenous glycoprotein IIb/IIIa inhibitors, where they seemed to carry more bang for their buck in diabetic vs. non-diabetic patients. Perhaps we’re seeing the same thing here with ticagrelor,” he said.